Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
about
Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune toleranceAAV-mediated overexpression of human α7 integrin leads to histological and functional improvement in dystrophic miceDystrophin deficiency in canine X-linked muscular dystrophy in Japan (CXMDJ) alters myosin heavy chain expression profiles in the diaphragm more markedly than in the tibialis cranialis muscle.Transgene expression levels determine the immunogenicity of transduced hematopoietic grafts in partially myeloablated mice.Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle.Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal musclesInfluence of immune responses in gene/stem cell therapies for muscular dystrophies.Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys.Gene therapy for muscular dystrophies: progress and challengesSystemic delivery of genes to striated muscles using adeno-associated viral vectors.Transduction of skeletal muscles with common reporter genes can promote muscle fiber degeneration and inflammationGene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.Therapeutic approaches to muscular dystrophy.Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy.Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice.Immune responses to adeno-associated virus and its recombinant vectors.Gene therapy for muscular dystrophy - a review of promising progress.Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).Dysferlin and animal models for dysferlinopathyComplement is an essential component of the immune response to adeno-associated virus vectors.Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease.Emerging strategies for cell and gene therapy of the muscular dystrophiesCorrection of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy.Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy.Muscular dystrophy therapy by nonautologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammationTherapeutic advances in muscular dystrophyIn vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance.Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery.AAV-directed muscular dystrophy gene therapy.Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer.Viral vectors for therapy of neurologic diseases.Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive deliveryIntradermal Immunization with rAAV1 Vector Induces Robust Memory CD8(+) T Cell Responses Independently of Transgene Expression in DCs.Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles.Human α7 Integrin Gene (ITGA7) Delivered by Adeno-Associated Virus Extends Survival of Severely Affected Dystrophin/Utrophin-Deficient MiceTargeted Gene Addition of Microdystrophin in Mice Skeletal Muscle via Human Myoblast Transplantation.Construction and analysis of compact muscle-specific promoters for AAV vectors.Direct comparison of four adeno-associated virus serotypes in mediating the production of antiangiogenic proteins in mouse muscle.
P2860
Q27317882-6EC922DF-48C4-484A-9CA1-8482F33F5582Q28283362-520F77CF-A878-43E1-BB9B-C28506719173Q33313653-5A0CBC32-8815-47E1-ADAB-EA58DD57D1B2Q33496681-7E8ADC79-F1DE-4697-A09C-B38BB759417CQ33713019-C9EBCC56-5968-4957-BC37-B25CBFD91784Q33715654-C2E0A237-63B8-4ED8-A233-2333FA1B3F45Q33736192-B2618F84-174F-4025-A8BB-328C7B8016D5Q33847391-6A9D66F4-1177-4491-9514-D0C0EAD11543Q34180144-4F1F33A5-1ABD-4D23-B02C-9B7A2525325DQ34347199-EC919BAD-B82B-4ABB-A871-63A88D55EA12Q34517044-69263757-B332-4238-88EC-F21B55ACE3FBQ34566454-2FAC0BDA-9DEC-442B-8C40-DEC8F9AF3542Q34982869-F83799BA-4D77-4640-8601-2D5D8E3F27B6Q34984541-757B9941-3B1E-49F1-8FEC-BB6FAFDB8222Q35062311-6E42FF9C-5767-47E8-8BCB-4DFB003A4D66Q35083651-580D173D-A1A2-4FEE-A2D5-A041FAA3F67BQ35131229-5C0E38ED-0459-4A51-985F-7088E84954D0Q35184730-D5218938-A55C-4040-B9B1-BE391217AD82Q35904461-2A41A2FF-811A-4BC4-AB18-463E77ADB2EAQ36085192-3E645C48-458B-4134-82B8-57919F8010DEQ36484108-2C412F9F-E98C-41DA-A6E9-389DAE8F20B3Q36848984-CC33B3F7-AEBF-46F6-AAE2-0E1408D78E43Q36960845-53B017B2-720C-4066-BF72-0D4E959B9B8EQ37161996-CAEEC86D-E134-4320-8BED-F07B686B6F66Q37277411-B39906F6-EA16-425D-91AA-022B1721A227Q37352442-595F0387-F7A1-4AFA-B851-887D870DC385Q37455625-098A838A-4C96-497B-A7DC-961D61540BE1Q37472002-DBD16B9A-3BB0-42A1-98A2-E10FF4016739Q37562066-ECA4D204-AA7E-42A7-A7E1-B8585131F0DAQ37687423-FB9E9604-CA2E-4E95-B25D-97A2DF669121Q37743813-BFAC9836-2A82-4120-B5F4-5BD1EB87B558Q38539938-74D15EBF-D39B-4C21-86A2-EAA6CCFE2E90Q38746238-9CA56EF2-D316-4C12-9505-B7D6A0DA296FQ39500834-A3EE800F-8CFF-4B28-AE7C-48516443EE71Q40117829-67D517C5-B500-446D-B283-EE9493023756Q40667121-C14D5538-CFB1-4540-B9E3-A9235A717559Q41668084-61F1E733-3733-45AD-A906-3F8900AD2718Q41844091-AC18D274-4B73-4DED-A6A4-D990429806ECQ42437569-21E74311-25C5-4E9A-844B-D1B6F93E71B1Q43427810-760E2037-E39D-4048-9042-81C606F809E5
P2860
Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Adeno-associated virus vector- ...... against the transgene product.
@en
Adeno-associated virus vector- ...... against the transgene product.
@nl
type
label
Adeno-associated virus vector- ...... against the transgene product.
@en
Adeno-associated virus vector- ...... against the transgene product.
@nl
prefLabel
Adeno-associated virus vector- ...... against the transgene product.
@en
Adeno-associated virus vector- ...... against the transgene product.
@nl
P2093
P2860
P356
P1433
P1476
Adeno-associated virus vector- ...... against the transgene product.
@en
P2093
Chamberlain JS
Miyagoe-Suzuki Y
Sakamoto M
Tanouchi A
Yamamoto H
P2860
P2888
P304
P356
10.1038/SJ.GT.3301829
P577
2002-12-01T00:00:00Z
P5875
P6179
1006173053